Latest Breaking News On - Dermavant sciences - Page 5 : comparemela.com

Dermavant Sciences: Dermavant Announces Positive Results from Phase 4 Open-Label Trial of VTAMA (tapinarof) Cream, 1% for the Treatment of Plaque Psoriasis in the Head and Neck Region in Adults

Tapinarof Effective for AD in Patients as Young as 2 years

Tapinarof cream, 1%, an aryl hydrocarbon receptor agonist, was approved in 2022 for treating plaque psoriasis in adults.

Real World Data on Clinical Characteristics of Psoriasis Patients Treated with Tapinarof Cream

This research provides an early analysis of plaque psoriasis patients within routine clinical practice settings and outside of a clinical trial setting.

Can We Do More for Topical Therapy in Pediatric Atopic Dermatitis?

It's key for clinicians to optimize therapy prior to systemic agents.

Vitiligo Market Growth to Undergo Significant Changes by 2032, Predicts DelveInsight | Key Companies in the Market - Clinuvel Pharmaceuticals Limited, Pfizer, Incyte Corporation, Amgen

/PRNewswire/ DelveInsight s Vitiligo Market Insights report includes a comprehensive understanding of current treatment practices, vitiligo emerging drugs,.